Luminex Corporation

    Jurisdiction
    United States
    LEI
    5299004PD7MBYRVKM104
    ISIN
    US55027E1029 (LMNX)
    Sectors
    1. Healthcare
    2. Medical - Instruments & Supplies

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Read full profile

    Fundamentals

    Net revenue
    €373.30M
    Gross margin
    60.3%
    EBIT
    €46.28M
    EBIT margin
    12.4%
    Net income
    €20.13M
    Net margin
    5.4%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.10
    Ex date
    Payment date
    Dividend payout ratio
    72.4%

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: February 8, 2021 (Q4 2020)

    Add to watchlist

    Notifications